Hepatology International· 2017Q1
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
- 2,186citations
- Q1SCImago
- 2017year
Short summary
Updated clinical practice guidelines for hepatocellular carcinoma (HCC) management in the Asia-Pacific region have been released, offering evidence-based recommendations tailored for diverse medical environments.
AI-generated from the title and abstract; the full text is not read.
Key points
- Guidelines updated for HCC management in the Asia-Pacific region.
- Recommendations are evidence-based.
- Designed for diverse medical environments within the region.
- HCC is a leading public health problem in the Asia-Pacific.
AI-generated from the title and abstract; the full text is not read.
Abstract
There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the "Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines" meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.
The authors' abstract, as published at the source. Hepatology International, 2017 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Hepatology
HepatologyMedicine